目的 研究孟魯司特聯(lián)合布地奈德治療哮喘患兒的臨床療效。方法 選取2013年5月-2015年5月兒科收集治療的100例哮喘患兒作為研究對象，按照隨機奇偶數(shù)字法分為治療組和對照組，各50例；對照組患兒行布地奈德霧化治療，治療組患兒加用孟魯司特治療；分析比較兩組治療情況、肺功能改善、不良反應(yīng)等。結(jié)果 兩組肺功能比較，組內(nèi)治療后優(yōu)于治療前，差異顯著（P<0.05）；治療后治療組高于對照組，差異顯著（P<0.05）；治療組憋醒天數(shù)、咳嗽評分、哮喘評分均短于對照組，差異顯著（P<0.05）；不良反應(yīng)率比較：治療組14.0%低于對照組30.0%，差異顯著（P<0.05）。結(jié)論 孟魯司特聯(lián)合布地奈德對哮喘患兒的治療可明顯改善患兒肺功能，控制哮喘癥狀，且無嚴(yán)重不良反應(yīng)，具有較高的臨床應(yīng)用價值。

Objective To explore the clinical medication efficacy of montelukast for the treatment of children with asthma. Methods One hundred children with asthma admitted and treated by the Department of Pediatrics from May, 2013 to May, 2015 were selected as research subjects, who were divided into the treatment group and the control group according to random even-odd method with 50 cases in each group. Patients in the control group were subject to budesonide nebulization therapy, and patients in the treatment group were subject to montelukast plus treatment on the basis of that applied on patients in the control group. The treatment conditions, improvements of lung function and adverse reactions of patients in two groups were compared. Results Comparison in lung function of patients in two groups, the efficacy on patients after intra-group treatment was better than that before treatment, and the differences were significant (P<0.05). Indexes of patients in the treatment group after treatment were better than that of patients in the control group (P<0.05), and the difference was significant. The suppressive waken days, asthma score, and cough score of patients in the treatment group were shorter than those of patients in the control group (P<0.05), and the difference was significant. The comparison in the rate of adverse reactions was as follows: The rate of adverse reactions in the treatment group was 14.0% lower than that of patients in the control group at 30% (P<0.05), and the difference was significant. Conclusion The treatment for budesonide on children with asthma can obviously improve lung function and control symptoms of asthma without serious adverse reactions, delivering high clinical value.